Background We sought to describe the dosages of angiotensin-converting enzyme (ACE)
inhibitor prescribed to elderly patients with heart failure at hospital discharge, the factors …

Background The benefit of angiotensin-converting enzyme (ACE) inhibitors on mortality in
heart failure has been proved in randomized controlled trials. Methods We prospectively …

Background—Although ACE inhibitors are underprescribed for heart failure, factors
associated with their use are not well described. Furthermore, the effectiveness of ACE …

OBJECTIVE: To evaluate the dose‐related benefit of angiotensin‐converting enzyme (ACE)
inhibitor therapy among older adults with heart failure and to evaluate whether low‐dose …

Purpose: Although angiotensin-converting enzyme (ACE) inhibitors are recommended for all
patients with systolic heart failure, prior studies suggest that elderly cohorts are less likely to …

Background. The extent to which age plays a role in the underutilization of angiotensin-
converting enzyme (ACE) inhibitors in heart failure patients has not been well studied …

OBJECTIVES: The purpose of this study is to determine the association between discharge
use of angiotensin-converting enzyme (ACE) inhibitors in patients with perceived …

Background: Existing clinical trial data do not address whether all angiotensin-converting-
enzyme (ACE) inhibitors are similarly beneficial in improving survival and reducing the rate …

Background Evidence from clinical trials in the past decade has consistently shown that
angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients …

Background. There is a lack of information on the effects of angiotensin-converting enzyme
(ACE) inhibitors in very old people with heart failure (HF). The objective of this study is to …